CO6382142A2 - Combinación farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un anti-epileptico. - Google Patents

Combinación farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un anti-epileptico.

Info

Publication number
CO6382142A2
CO6382142A2 CO11018461A CO11018461A CO6382142A2 CO 6382142 A2 CO6382142 A2 CO 6382142A2 CO 11018461 A CO11018461 A CO 11018461A CO 11018461 A CO11018461 A CO 11018461A CO 6382142 A2 CO6382142 A2 CO 6382142A2
Authority
CO
Colombia
Prior art keywords
methyl
component
phenol
propil
etil
Prior art date
Application number
CO11018461A
Other languages
English (en)
Spanish (es)
Inventor
Petra Bloms-Fluke
Klaus Schiene
Thomas Christoph
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6382142(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of CO6382142A2 publication Critical patent/CO6382142A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CO11018461A 2008-09-05 2011-02-16 Combinación farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un anti-epileptico. CO6382142A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05

Publications (1)

Publication Number Publication Date
CO6382142A2 true CO6382142A2 (es) 2012-02-15

Family

ID=40345058

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11018461A CO6382142A2 (es) 2008-09-05 2011-02-16 Combinación farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un anti-epileptico.

Country Status (28)

Country Link
US (1) US20100063148A1 (enExample)
EP (2) EP2331210B1 (enExample)
JP (4) JP5731387B2 (enExample)
KR (3) KR101730924B1 (enExample)
CN (2) CN105520924B (enExample)
AR (2) AR073361A1 (enExample)
AU (3) AU2009289776A1 (enExample)
BR (1) BRPI0920521A2 (enExample)
CA (1) CA2735857C (enExample)
CL (1) CL2011000317A1 (enExample)
CO (1) CO6382142A2 (enExample)
CY (2) CY1115751T1 (enExample)
DK (2) DK2331210T3 (enExample)
EC (1) ECSP11010869A (enExample)
ES (2) ES2513394T3 (enExample)
HR (2) HRP20140663T1 (enExample)
HU (1) HUE043278T2 (enExample)
IL (3) IL211135A (enExample)
LT (1) LT2735338T (enExample)
MX (1) MX2011002339A (enExample)
PE (5) PE20110291A1 (enExample)
PL (2) PL2331210T3 (enExample)
PT (2) PT2331210E (enExample)
RU (2) RU2571501C2 (enExample)
SI (2) SI2331210T1 (enExample)
TR (1) TR201904388T4 (enExample)
WO (1) WO2010025931A2 (enExample)
ZA (1) ZA201101449B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
PL2462990T3 (pl) 2006-06-15 2014-05-30 Ucb Pharma Gmbh Kompozycja farmaceutyczna obejmująca lakozamid i lewetyracetam o synergistycznym działaniu przeciwdrgawkowym
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
LT2735338T (lt) * 2008-09-05 2019-04-10 Grünenthal GmbH 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolio ir pregabalino arba gabapentino farmacinis derinys
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
EP2590636A1 (en) 2010-07-06 2013-05-15 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
JP5786714B2 (ja) 2010-07-30 2015-09-30 東レ株式会社 神経障害性疼痛の治療剤又は予防剤
EA028149B1 (ru) * 2011-03-04 2017-10-31 Грюненталь Гмбх Парентеральное введение тапентадола
ES2712072T3 (es) * 2011-07-20 2019-05-09 Torrent Pharmaceuticals Ltd Composición farmacéutica de tapentadol
PT2736501T (pt) * 2011-07-29 2018-03-26 Gruenenthal Gmbh Administração intratecal ou epidural de 3-[(1s,2s)-3-(dimetilamino)-1-etil-2-metilpropil]fenol
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9629818B2 (en) * 2012-11-01 2017-04-25 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol for parenteral administration
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
RU2020128323A (ru) 2015-12-22 2020-10-06 Зодженикс Интернэшнл Лимитед Фенфлураминовые композиции и способы их получения
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
KR20250040753A (ko) * 2016-08-24 2025-03-24 조게닉스 인터내셔널 리미티드 5-ht2b 작용물질의 형성을 억제하기 위한 제제 및 그것의 사용 방법
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3883555A1 (en) 2018-11-19 2021-09-29 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
JP4977297B2 (ja) * 1999-08-20 2012-07-18 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トラマドール物質及び抗痙攣薬を含んで成る組成物
AU2003210486B2 (en) * 2002-01-16 2007-06-28 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
IL162932A0 (en) * 2002-02-22 2005-11-20 Warner Lambert Co Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2007005716A2 (en) 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
MX2008013828A (es) * 2006-04-28 2008-11-10 Gruenenthal Gmbh Combinacion farmaceutica que comprende 3-(3-dimetilanimo-1-etil-2- metil-propil)-fenol y un nsaid.
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
WO2009067703A2 (en) * 2007-11-23 2009-05-28 Nectid, Inc. Tapentadol compositions
JP5291123B2 (ja) * 2008-01-25 2013-09-18 ゼノポート，インコーポレイティド （３ｓ）−アミノメチル−５−ヘキサン酸プロドラッグの結晶形態及びその使用
LT2735338T (lt) * 2008-09-05 2019-04-10 Grünenthal GmbH 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolio ir pregabalino arba gabapentino farmacinis derinys

Also Published As

Publication number Publication date
PE20142357A1 (es) 2015-02-04
KR20160086981A (ko) 2016-07-20
CA2735857C (en) 2019-05-28
AU2016203053B2 (en) 2018-01-25
EP2735338A1 (en) 2014-05-28
RU2571501C2 (ru) 2015-12-20
AU2018202879B2 (en) 2020-03-12
AU2009289776A1 (en) 2010-03-11
IL237392B (en) 2019-08-29
KR101730924B1 (ko) 2017-04-27
IL211135A0 (en) 2011-04-28
US20100063148A1 (en) 2010-03-11
ES2719900T3 (es) 2019-07-16
CN105520924A (zh) 2016-04-27
PL2331210T3 (pl) 2014-12-31
CY1115751T1 (el) 2017-01-25
HUE043278T2 (hu) 2019-08-28
CN102159284B (zh) 2015-12-09
EP2331210B1 (en) 2014-07-09
KR20110057144A (ko) 2011-05-31
PT2331210E (pt) 2014-08-25
DK2331210T3 (da) 2014-08-11
AU2018202879A1 (en) 2018-05-17
AR117613A2 (es) 2021-08-18
AR073361A1 (es) 2010-11-03
JP2017071636A (ja) 2017-04-13
CN102159284A (zh) 2011-08-17
CA2735857A1 (en) 2010-03-11
AU2016203053A1 (en) 2016-06-02
WO2010025931A3 (en) 2010-06-17
JP2019131578A (ja) 2019-08-08
SI2331210T1 (sl) 2014-10-30
ES2513394T3 (es) 2014-10-27
IL211135A (en) 2017-09-28
TR201904388T4 (tr) 2019-05-21
EP2735338B1 (en) 2019-02-06
JP2015096530A (ja) 2015-05-21
JP5731387B2 (ja) 2015-06-10
CL2011000317A1 (es) 2011-06-17
SI2735338T1 (sl) 2019-04-30
ECSP11010869A (es) 2011-04-29
IL237392A0 (en) 2015-04-30
CY1121492T1 (el) 2020-05-29
KR101641519B1 (ko) 2016-07-21
HK1159011A1 (en) 2012-07-27
RU2011112444A (ru) 2012-10-10
WO2010025931A2 (en) 2010-03-11
PE20110291A1 (es) 2011-06-04
PE20190914A1 (es) 2019-06-26
KR20170048602A (ko) 2017-05-08
HRP20190500T1 (hr) 2019-08-09
CN105520924B (zh) 2019-04-09
RU2674150C1 (ru) 2018-12-05
JP2012501986A (ja) 2012-01-26
PT2735338T (pt) 2019-05-24
DK2735338T3 (en) 2019-04-23
EP2331210A2 (en) 2011-06-15
IL237391A0 (en) 2015-04-30
HRP20140663T1 (hr) 2014-10-10
BRPI0920521A2 (pt) 2018-01-16
HK1198145A1 (en) 2015-03-13
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
PE20142372A1 (es) 2015-02-04
ZA201101449B (en) 2011-10-26
MX2011002339A (es) 2011-04-04
PE20142371A1 (es) 2015-02-04
PL2735338T3 (pl) 2019-07-31
IL237391A (en) 2017-12-31

Similar Documents

Publication Publication Date Title
AR117613A2 (es) Combinación farmacéutica
ECSP19047259A (es) Combinación farmacéutica para el tratamiento del dolor
UY32925A (es) Composiciones de corticosteroides de administración oral
ECSP088873A (es) Combinación farmaceutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil) fenol y nsaid
MX362693B (es) Composición para el cuidado oral para tratar y/o prevenir afecciones causadas por microorganismos, usando un dispositivo oral de luz.
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
CR20150326A (es) Inhibidores de autotaxina
DOP2013000252A (es) FORMULACION PARA ANTICUERPO ANTI-a4ß7
MD4577B1 (ro) Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CR11418A (es) Trans-clomifeno para el sindrome metabolico
ECSP109984A (es) Composición farmacéutica mejorada que contiene dihidropiridina, antagonista del canal de calcio y el método para su preparación
CY1123382T1 (el) Απο του στοματος και ενεσιμα και σκευασματα ενωσεων τετρακυκλινης
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
AR086395A1 (es) Envase para el tratamiento de patologias
AR077987A1 (es) Combinacion farmaceutica que comprende 6-dimetilaminometil-1-(3-metoxifenil)-ciclohexano-1,3-diol o 6-dimetilaminometil-1-(3-hidroxifenil)-ciclohexano-1,3-diol y un antiepileptico
CO7151497A2 (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos
CO6341550A2 (es) Combinacion farmaceutica que contiene el 6 - dimetilaminometil - 1 - (3-metoxi-fenil) - ciclohexano - 1,3 - diol y un nsaid.
ECSP11010876A (es) Combinación farmacéutica que contiene el 6-dimetilaminometil-1-(3-metoxi-fenil)-ciclohexano-1,3-diol y paracetamol
ECSP099734A (es) Composición farmaceutica que comprende la combinación de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
DOP2013000004A (es) Agentes terapeuticos 976
GT201400115A (es) Combinación farmacéutica antineurítica y composición
ES2485540B1 (es) Compuestos útiles en el tratamiento de la aciduría metilmalónica

Legal Events

Date Code Title Description
FG Application granted